Post hoc analyses of BIMZELX (bimekizumab-bkzx) using the first consensus definition of psoriasis on-treatment remission:
Published by the National Psoriasis Foundation (NPF), this first consensus definition requires stringent criteria for complete skin clearance (continuous maintenance of BSA=0% or IGA=0) to be met for at least six months
62.6% and 64.9% of those receiving BIMZELX achieved NPF-defined on-treatment remission for at least six months in the first year of BE RADIANT and BE VIVID, respectively*
Durable and complete skin clearance with BIMZELX retreatment: In a separate post hoc analysis, of those who relapsed after stopping treatment, 83.6% achieved PASI 100 at four years after being retreated with BIMZELX**
ATLANTA, March 27, 2026 /PRNewswire/ — UCB, a global biopharmaceutical company, today announced new data in moderate-to-severe plaque psoriasis (PSO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, March 27–31. These data assess BIMZELX® (bimekizumab-bkzx) in providing on-treatment remission, as defined by the National Psoriasis Foundation (NPF), and complete skin clearance up to four years with retreatment after stopping treatment.1-2
“The recent National Psoriasis Foundation definition of on-treatment remission provides clinicians with a benchmark in routine practice, helping them feel confident that those living with psoriasis can reach and maintain minimal or no disease,” said Dr. April Armstrong, Professor and Chief of Dermatology at The University of California, Los Angeles (UCLA). “Achieving complete skin clearance can ease the significant burden of symptoms and meaningfully improve daily life for those affected by this chronic condition.”
“Achieving sustained inflammation control and complete skin clearance is our goal for people living with psoriasis, and generating the evidence to support that progress is fundamental to advancing care,” said Donatello Crocetta, Chief Medical Officer, UCB. “At the same time, continuity of treatment may not always be possible in real-world clinical practice. These findings show high response rates following retreatment with bimekizumab and indicate potential to re-establish disease control without meaningfully impacting long-term outcomes.”
In a post-hoc analysis of the first year of BE RADIANT and BE VIVID, 62.6% and 64.9% (N=289/N=242, respectively) of PSO patients treated with BIMZELX achieved NPF-defined on-treatment remission during any ≥6-month period.1* At Week 28, the earliest timepoint at which remission could be observed across both BE RADIANT and BE VIVID, 10.4% and 12.4% of patients in BE RADIANT and BE VIVID, respectively, treated with BIMZELX achieved NPF-defined remission.1*
In a separate post hoc analysis, data reported from the BE READY Phase 3 trial and the BE BRIGHT open-label extension (OLE) showed that among patients treated with BIMZELX 320mg Q4W who achieved PASI 90 at Week 16 and stopped treatment (N=105), 31.4% (33/105) maintained at least a PASI 75 response to Week 56.2** In those who lost PASI 75 response (66/105) before Week 56, 63.1% (41/65) achieved complete skin clearance (PASI 100) after 12 weeks of retreatment with BIMZELX.2** At four years, complete skin clearance was maintained by 83.6% (46/55) of patients who were retreated with BIMZELX.2**
These data form part of UCB’s broader presence at the 2026 AAD Annual Meeting, where a total of eleven abstracts will be presented across the BIMZELX portfolio in psoriasis, hidradenitis suppurativa, psoriatic arthritis and axial spondyloarthritis.
*Observed case (OC): Data are reported as observed case. The data reported are from a post-hoc analyses of two Phase 3 trials, BE VIVID and BE RADIANT.1 Patients who completed the double-blinded periods of BE VIVID (52 weeks) and BE RADIANT (48 weeks) were included.1 In BE VIVID, patients were randomized to BIMZELX 320mg every 4 weeks (Q4W) or ustekinumab 45/90mg (≤100kg/>100kg) at Week 0, Week 4, then Q12W.3 In BE RADIANT, patients were randomized to BIMZELX Q4W to Week 16, then Q4W or Q8W thereafter, or secukinumab 300mg weekly to Week 4 then Q4W;4 BIMZELX Q4W and Q8W data were pooled. Proportions achieving NPF-defined remission (either continuous BSA=0% for ≥6 months or IGA=0 for ≥6 months) during the first year of BE VIVID/BE RADIANT, with no missing BSA/IGA measurements, are reported (observed case).1 These data were post hoc analyses and should be interpreted with caution as the analyses were not prespecified in the original protocols.
**Observed case (OC): Data are reported as observed case. Data are reported from the BE READY Phase 3 trial/BE BRIGHT open-label extension (OLE).2 Patients randomized to BIMZELX 320mg every 4 weeks (Q4W), who achieved PASI 90 at Week 16, were then rerandomized to placebo for a 40-week randomized-withdrawal period before OLE entry.2 Patients maintaining at least PASI 75 continued placebo to Week 56, switching to BIMZELX Q4W in the OLE.2 Relapsing patients (